These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

361 related articles for article (PubMed ID: 26317899)

  • 21. Stromal PD-L1 Expression Is Associated With Better Disease-Free Survival in Triple-Negative Breast Cancer.
    Li X; Wetherilt CS; Krishnamurti U; Yang J; Ma Y; Styblo TM; Meisel JL; Peng L; Siddiqui MT; Cohen C; Aneja R
    Am J Clin Pathol; 2016 Oct; 146(4):496-502. PubMed ID: 27686176
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prognostic significance of PD-L1 and PD-L2 in breast cancer.
    Baptista MZ; Sarian LO; Derchain SF; Pinto GA; Vassallo J
    Hum Pathol; 2016 Jan; 47(1):78-84. PubMed ID: 26541326
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prognostic impact of programmed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor-infiltrating lymphocytes in ovarian high grade serous carcinoma.
    Darb-Esfahani S; Kunze CA; Kulbe H; Sehouli J; Wienert S; Lindner J; Budczies J; Bockmayr M; Dietel M; Denkert C; Braicu I; Jöhrens K
    Oncotarget; 2016 Jan; 7(2):1486-99. PubMed ID: 26625204
    [TBL] [Abstract][Full Text] [Related]  

  • 24. CD274 (PDL1) and JAK2 genomic amplifications in pulmonary squamous-cell and adenocarcinoma patients.
    Clavé S; Pijuan L; Casadevall D; Taus Á; Gimeno J; Hernández-Llodrà S; Rodríguez-Rivera M; Lorenzo M; Menéndez S; Albanell J; Espinet B; Arriola E; Salido M
    Histopathology; 2018 Jan; 72(2):259-269. PubMed ID: 28795418
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Genetic Basis for PD-L1 Expression in Squamous Cell Carcinomas of the Cervix and Vulva.
    Howitt BE; Sun HH; Roemer MG; Kelley A; Chapuy B; Aviki E; Pak C; Connelly C; Gjini E; Shi Y; Lee L; Viswanathan A; Horowitz N; Neuberg D; Crum CP; Lindeman NL; Kuo F; Ligon AH; Freeman GJ; Hodi FS; Shipp MA; Rodig SJ
    JAMA Oncol; 2016 Apr; 2(4):518-22. PubMed ID: 26913631
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Adipogenesis in triple-negative breast cancer is associated with unfavorable tumor immune microenvironment and with worse survival.
    Oshi M; Tokumaru Y; Angarita FA; Lee L; Yan L; Matsuyama R; Endo I; Takabe K
    Sci Rep; 2021 Jun; 11(1):12541. PubMed ID: 34131208
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The repertoire of somatic genetic alterations of acinic cell carcinomas of the breast: an exploratory, hypothesis-generating study.
    Guerini-Rocco E; Hodi Z; Piscuoglio S; Ng CK; Rakha EA; Schultheis AM; Marchiò C; da Cruz Paula A; De Filippo MR; Martelotto LG; De Mattos-Arruda L; Edelweiss M; Jungbluth AA; Fusco N; Norton L; Weigelt B; Ellis IO; Reis-Filho JS
    J Pathol; 2015 Oct; 237(2):166-78. PubMed ID: 26011570
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Molecular and Immune Correlates of PDCD1 (PD-1), PD-L1 (CD274), and PD-L2 (PDCD1LG2) DNA Methylation in Triple Negative Breast Cancer.
    Ralser DJ; Klümper N; Gevensleben H; Zarbl R; Kaiser C; Landsberg J; Hölzel M; Strieth S; Faridi A; Abramian A; Dietrich D
    J Immunother; 2021 Oct; 44(8):319-324. PubMed ID: 34347720
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immune checkpoint blockade as a potential therapeutic strategy for undifferentiated malignancies.
    Devereaux KA; Charu V; Zhao S; Charville GW; Bangs CD; van de Rijn M; Cherry AM; Natkunam Y
    Hum Pathol; 2018 Dec; 82():39-45. PubMed ID: 30539796
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prognostic value of microRNA-9 and microRNA-155 expression in triple-negative breast cancer.
    Jang MH; Kim HJ; Gwak JM; Chung YR; Park SY
    Hum Pathol; 2017 Oct; 68():69-78. PubMed ID: 28882698
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Durable clinical response to the multidisciplinary management of neurosurgery, radiation and chemoimmunotherapy in a patient with PD-L1/PD-L2/JAK2 (PDJ)-amplified, refractory triple-negative breast cancer.
    Zhao H; Ma W; Fragoso RC; Iv GRH; Ashok A; Li T
    J Natl Cancer Cent; 2021 Sep; 1(3):115-121. PubMed ID: 39036375
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Genomic alterations of the JAK2 and PDL loci occur in a broad spectrum of lymphoid malignancies.
    Van Roosbroeck K; Ferreiro JF; Tousseyn T; van der Krogt JA; Michaux L; Pienkowska-Grela B; Theate I; De Paepe P; Dierickx D; Doyen C; Put N; Cools J; Vandenberghe P; Wlodarska I
    Genes Chromosomes Cancer; 2016 May; 55(5):428-41. PubMed ID: 26850007
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Expression of epithelial-mesenchymal transition-related markers in triple-negative breast cancer: ZEB1 as a potential biomarker for poor clinical outcome.
    Jang MH; Kim HJ; Kim EJ; Chung YR; Park SY
    Hum Pathol; 2015 Sep; 46(9):1267-74. PubMed ID: 26170011
    [TBL] [Abstract][Full Text] [Related]  

  • 34. TTK is a favorable prognostic biomarker for triple-negative breast cancer survival.
    Xu Q; Xu Y; Pan B; Wu L; Ren X; Zhou Y; Mao F; Lin Y; Guan J; Shen S; Zhang X; Wang C; Zhong Y; Zhou L; Liang Z; Zhao H; Sun Q
    Oncotarget; 2016 Dec; 7(49):81815-81829. PubMed ID: 27833085
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Gene expression patterns through oral squamous cell carcinoma development: PD-L1 expression in primary tumor and circulating tumor cells.
    Oliveira-Costa JP; de Carvalho AF; da Silveira da GG; Amaya P; Wu Y; Park KJ; Gigliola MP; Lustberg M; Buim ME; Ferreira EN; Kowalski LP; Chalmers JJ; Soares FA; Carraro DM; Ribeiro-Silva A
    Oncotarget; 2015 Aug; 6(25):20902-20. PubMed ID: 26041877
    [TBL] [Abstract][Full Text] [Related]  

  • 36. High PD-L1 expression was associated with poor prognosis in 870 Chinese patients with breast cancer.
    Qin T; Zeng YD; Qin G; Xu F; Lu JB; Fang WF; Xue C; Zhan JH; Zhang XK; Zheng QF; Peng RJ; Yuan ZY; Zhang L; Wang SS
    Oncotarget; 2015 Oct; 6(32):33972-81. PubMed ID: 26378017
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Patterns of PD-1, PD-L1, and PD-L2 expression in pediatric solid tumors.
    Pinto N; Park JR; Murphy E; Yearley J; McClanahan T; Annamalai L; Hawkins DS; Rudzinski ER
    Pediatr Blood Cancer; 2017 Nov; 64(11):. PubMed ID: 28488345
    [TBL] [Abstract][Full Text] [Related]  

  • 38. PD-L1 expression and prognostic impact in glioblastoma.
    Nduom EK; Wei J; Yaghi NK; Huang N; Kong LY; Gabrusiewicz K; Ling X; Zhou S; Ivan C; Chen JQ; Burks JK; Fuller GN; Calin GA; Conrad CA; Creasy C; Ritthipichai K; Radvanyi L; Heimberger AB
    Neuro Oncol; 2016 Feb; 18(2):195-205. PubMed ID: 26323609
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [New molecular classification of colorectal cancer, pancreatic cancer and stomach cancer: Towards "à la carte" treatment?].
    Dreyer C; Afchain P; Trouilloud I; André T
    Bull Cancer; 2016; 103(7-8):643-50. PubMed ID: 27345450
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinicopathological analysis of PD-L1 and PD-L2 expression in pulmonary squamous cell carcinoma: Comparison with tumor-infiltrating T cells and the status of oncogenic drivers.
    Kim MY; Koh J; Kim S; Go H; Jeon YK; Chung DH
    Lung Cancer; 2015 Apr; 88(1):24-33. PubMed ID: 25662388
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.